Pages that link to "Q57321728"
Jump to navigation
Jump to search
The following pages link to Philip J Lowe (Q57321728):
Displaying 30 items.
- Visualization and communication of pharmacometric models with berkeley madonna (Q29584444) (← links)
- Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects (Q34782224) (← links)
- From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics (Q34901024) (← links)
- Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. (Q35183644) (← links)
- On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. (Q36055566) (← links)
- Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. (Q36213735) (← links)
- Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. (Q36354544) (← links)
- In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes (Q37273133) (← links)
- On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. (Q37668661) (← links)
- Omalizumab in asthma: an update on recent developments (Q38248469) (← links)
- A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. (Q41125439) (← links)
- Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies. (Q41150827) (← links)
- Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. (Q41701492) (← links)
- Rapid kinetic analysis of the bile-salt-dependent secretion of phospholipid, cholesterol and a plasma-membrane enzyme into bile. (Q42012019) (← links)
- Effect of taurochenodeoxycholate or tauroursodeoxycholate upon biliary output of phospholipids and plasma-membrane enzymes, and the extent of cell damage, in isolated perfused rat livers. (Q42037201) (← links)
- Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. (Q42536548) (← links)
- Biliary protein output by isolated perfused rat livers. Effects of bile salts (Q42869519) (← links)
- Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. (Q43635728) (← links)
- P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized (Q45785904) (← links)
- Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. (Q48511386) (← links)
- Applying physiological and biochemical concepts to optimize biological drug development. (Q51722492) (← links)
- Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. (Q51776850) (← links)
- Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments (Q58900301) (← links)
- Colonic absorption of human calcitonin in man (Q67508391) (← links)
- Breakdown of hepatic tight junctions during reoxygenation injury (Q68153751) (← links)
- Fluorescence anisotropy from diphenylhexatriene in rat liver plasma membranes (Q70447137) (← links)
- Membrane damage caused by bile salts [proceedings] (Q71183513) (← links)
- Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats (Q72896956) (← links)
- New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin (Q80892285) (← links)
- Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations (Q83160769) (← links)